好色先生

好色先生

Explore the latest content from across our publications
Join The AAN

Log In

Forgot Password?
Create New Account

Loading... please wait

2025 Annual Meeting | Industry Theraepeutic Update from Novartis Pharmaceuticals: From data to experience: Early considerations for an established B-cell therapy for RMS with long-term patient results

Monday 04/07/25
11:45 AM - 12:45 PM PDT Add To Calendar
San Diego Convention Center | 6DE
This program will be presented in-person only
This program is not expected to be available in the meeting's On Demand product.
Industry Therapeutic Update
Stephen W. Yeung, DO, Christine Racchini, PharmD
General Neurology, Multiple Sclerosis
Bridging data and patient experience to deliver practical insights for the early use of an established B-cell therapy in patients with RMS.
This program is NOT accredited for continuing education by any organization. Additionally, Industry Therapeutic Updates program content and the views expressed herein are those of the presenting corporate entity and not of the AAN. These programs are not an official part of the 2025 AAN Annual Meeting education or scientific programs, nor are they endorsed by the AAN. The AAN cannot affirm claims pertaining to FDA off-label medication, research use of pre-FDA drugs, or other research information that might be discussed. Industry Therapeutic Updates are industry events.
No CME available

Program Materials Program Evaluations

Event Timeline
11:45 AM - 12:45 PM PDT Speaker Industry Theraepeutic Update from Novartis Pharmaceuticals: From data to experience: Early considerations for an established B-cell therapy for RMS with long-term patient results
Faculty Disclosures
Stephen W. Yeung, DO Dr. Yeung has received personal compensation for serving as an employee of Novartis.
Christine Racchini, PharmD No disclosure on file